Skip to main content
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. — Investor Relations & Filings

Ticker · TCRX ISIN · US89854M1018 US Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2024-04-15 Regulatory Filings
Country US United States of America
Listing US TCRX

About TScan Therapeutics, Inc.

https://www.tscan.com

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's approach is centered on discovering highly effective, naturally occurring TCRs and using them to genetically reprogram T cells. This strategy aims to harness the power of the human immune system to deliver safe and effective immunotherapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-04-15 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter from TScan Therapeutics, Inc. to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It references Rule 461 under the Securities Act of 1933 and is a formal communication related to the registration process of securities. The document is short (1379 characters) and does not contain financial statements or detailed financial data. It is an official regulatory communication rather than a financial report or announcement of results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-04-10 English
10-K/A
Annual Report FY 2023
2024-04-10 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 8, 2024, for TScan Therapeutics, Inc. The key content is the announcement of a change in senior management: the appointment of a new Chief Medical Officer and the departure of the previous one. There is no financial data or detailed report content, only a press release attached as an exhibit. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management. The document length is 3317 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2024-04-08 English
Regulatory Filings 2024
Regulatory Filings
2024-03-07 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC by TScan Therapeutics, Inc. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for sale to the public. The document includes a prospectus describing the securities to be offered, risk factors, and other related information. It is not an annual report, earnings release, or any other financial report but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, confirming it is a full registration statement filing.
2024-03-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.